TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·November 7, 2026

United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts

United Therapeutics combines a cash-rich balance sheet with record Tyvaso sales and multiple late-stage catalysts, but concentration in its flagship franchise keeps execution risk elevated. The stock looks fairly valued for a high-quality specialty biopharma with meaningful upside tied to 2027 regulatory decisions.

Research ReportUTHRHealthcareDrug Manufacturers - Specialty & GenericBiopharma
By TickerSpark·November 7, 2026·

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

17 min read
United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts
B+
Overall
A+
Balance Sheet
B+
Income
B+
Estimates
B
Valuation
TickerSpark AI RatingBuy
▌Investment Summary
United Therapeutics (UTHR) looks like a good investment right now, earning an overall grade of B+ and a Buy rating. Our fair value is $675, supported by record Tyvaso revenue, a cash-rich balance sheet, and multiple late-stage pipeline catalysts, though concentration risk remains a key watchpoint.

Thesis

United Therapeutics Corporation (UTHR) is a high-quality specialty biopharma with a strong balance sheet, an established pulmonary hypertension franchise, and several late-stage opportunities that extend beyond its current $3.18B commercial base. The investment case rests on three facts: Tyvaso generated record Q3 2026 revenue of $503.8M, the company held $1.56B of cash against $7.3M of reported debt at year-end 2025, and FDA decisions for nebulized Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension are scheduled for April 26, 2027 and June 24, 2027.

The central risk is concentration. Tyvaso represented 59.0% of 2025 revenue, while 2026 earnings have shown pressure: Q3 diluted EPS fell to $5.71 from $7.16 a year earlier, and net income declined to $258.6M from $338.7M. The latest quarter still produced record revenue of $832.5M, but the earnings profile is not as smooth as the revenue line.

At approximately $565, UTHR trades at 21.2x trailing earnings and 17.9x forward earnings. That valuation is reasonable for a cash-rich company with a differentiated commercial franchise, but a PEG ratio of 2.2 and year-over-year earnings growth of negative 20.3% argue against treating the stock as a bargain. The appropriate stance for a moderate-risk, medium-term investor is Buy, with meaningful attention to execution around Tyvaso, IPF, and ralinepag.

Company Overview

United Therapeutics, founded in 1996 and headquartered in Silver Spring, Maryland, develops and commercializes therapies for chronic and life-threatening diseases. The company employs approximately 1,400 people and operates in specialty pharmaceuticals, with its commercial business centered on pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and related cardiopulmonary conditions.

The marketed portfolio includes Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and the Remunity Pump. United Therapeutics also develops xenotransplantation and regenerative medicine programs, including gene-edited porcine kidneys and hearts. Those programs are long-dated options rather than current revenue engines, while Tyvaso remains the operating center of gravity.

▌Common Questions

Frequently asked questions

+Is UTHR stock a buy right now?
Yes, UTHR is a Buy right now. The company earns an overall B+ grade thanks to a fortress balance sheet, record Tyvaso sales, and a pipeline with meaningful 2027 catalysts, even though earnings have been choppier than revenue.
+What is UTHR's fair value?
United Therapeutics' fair value is $675. That level reflects the company’s 21.2x trailing earnings and 17.9x forward earnings profile, balanced against record Tyvaso revenue, a 2.2 PEG ratio, and the market’s need to price in both concentration risk and the potential upside from IPF and ralinepag approvals.
+
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Management described 14 programs in development during the November 4, 2026 corporate update. The stated strategy is to build a broader cardiopulmonary and respiratory franchise through nebulized therapies, dry-powder inhalers, soft-mist inhalers, once-daily medicines, and combination products. That strategy gives UTHR more growth avenues, but it also places greater demands on regulatory execution and manufacturing capacity.

Business Segment Deep Dive

UTHR reports a product-based business rather than a collection of separately managed operating segments. In 2025, Tyvaso produced $1.88B of revenue, followed by Remodulin at $526.8M, Orenitram at $496.9M, Unituxin at $226.8M, Adcirca at $30.0M, and Product and Service, Other at $24.0M.

The mix is shifting toward Tyvaso. Tyvaso increased from 56.3% of revenue in 2024 to 59.0% in 2025, while Remodulin declined from 18.7% to 16.6%. Orenitram reached a record $145M in Q3 2026 and delivered its 19th consecutive quarter of year-over-year revenue growth according to the investor presentation.

Q3 2026 product revenue showed a clear hierarchy. The Tyvaso franchise generated $503.8M, Orenitram generated $145M, Remodulin generated $122M, and Unituxin generated $52M. Tyvaso and Orenitram supplied the strongest commercial momentum, while Remodulin and Adcirca face greater exposure to mature-product and generic competition.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

Tyvaso is the flagship product and the primary growth engine. Q3 2026 Tyvaso revenue rose 5% year over year to $503.8M, with Tyvaso DPI growth partly offset by lower nebulized Tyvaso sales. United Therapeutics reported $496M of combined U.S. Tyvaso revenue, up 6% year over year.

The product's commercial advantage combines an established inhaled treprostinil therapy with a more convenient delivery format. Management said the 80-microgram cartridge provides the equivalent of 15 nebulized breaths in one breath. Among patients who started Tyvaso DPI after the higher-strength cartridges were introduced, about one in three reached higher doses, twice the previous rate.

The settlement involving Liquidia's YUTREPIA removed PH-ILD from the competing product's label and prohibited promotion into that indication. Management said near-term patient switching from YUTREPIA should be moderate because existing patients are not required to switch. The larger commercial opportunity is therefore new prescriptions and greater physician awareness in an under-penetrated PH-ILD market.

The product is not without risk. The Q3 earnings context states that competitive therapies negatively affected sales of nebulized Tyvaso, Tyvaso DPI, and Remodulin. Tyvaso's growing share of company revenue makes continued prescription growth and successful label expansion important to the entire equity story.

Innovation & Competitive Advantage

UTHR's strongest competitive advantage is the combination of clinical experience, physician relationships, specialized commercialization, and drug-device know-how. Management said the company's intellectual property includes fibrosis-related patents, device protections, and composition-of-matter protection for ralinepag, with many protections extending into the 2040s.

The TETON program strengthens the IPF opportunity. TETON-1 reported a Hodges-Lehmann estimate of 130.1 mL with a 95% confidence interval of 82.2 to 178.1 and P < 0.0001. TETON-2 reported a 95.6 mL estimate with a 95% confidence interval of 52.2 to 139.0 and P < 0.0001. The integrated analysis reported a 31% reduction in clinical-worsening risk and a 48% reduction in acute IPF exacerbation risk versus placebo.

Ralinepag adds a new oral PAH platform. The FDA accepted the ralinepag NDA with a June 24, 2027 PDUFA date, and UTHR bought down the related royalty economics. The company is also pursuing inhaled ralinepag formulations for PH-ILD, IPF, and progressive pulmonary fibrosis, although those programs remain earlier in development.

Innovation execution has produced one setback. UTHR moved the soft-mist inhaler NDA submission into 2027 after an FDA discussion identified a need for additional data. The company also said FDA feedback on its triple oral pill required a review of alternative development and filing paths. These delays do not impair the current Tyvaso franchise, but they reduce the certainty of the next product cycle.

Operations & Supply Chain

The Q3 2026 commercial result was driven by operating execution rather than inventory or seasonality. Management said there were no meaningful inventory or seasonal effects in the quarter. The expanded sales force improved reach and frequency, while referrals, starts, dosing, and physician engagement supported Tyvaso demand.

Management reported more than 1,000 referrals for a UTHR product in October 2026, the highest monthly total in company history. That metric supports the argument that sales-force investment is improving the commercial funnel, although referrals convert into revenue over time rather than immediately.

Supply-chain risk is concentrated in the ralinepag program. The company's API supplier received an Official Action Indicated compliance status after an inspection. UTHR is working with the supplier on corrective actions and said alternative plans are progressing in parallel. This is a concrete execution risk ahead of the June 2027 PDUFA date.

Market Analysis

UTHR is expanding from pulmonary hypertension into larger fibrotic-lung indications. Management identified approximately 1 million people in the United States across IPF, progressive pulmonary fibrosis, and PH-COPD as the combined populations under pursuit. This creates a larger addressable market than the company's historical PAH focus.

The near-term market expansion is tied to regulatory milestones rather than broad industry growth. The FDA accepted the supplemental NDA for nebulized Tyvaso in IPF with an April 26, 2027 PDUFA date. TETON-PPF reached full enrollment, and the investor presentation identifies topline data as a future milestone.

The market also rewards convenience. Tyvaso DPI, higher-dose cartridges, soft-mist inhalers, and oral ralinepag address different administration preferences within specialty care. UTHR's stated philosophy of approving a therapy and then improving its delivery format gives the company a practical path to extend existing franchises rather than relying only on entirely new molecules.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

UTHR serves patients with chronic and life-threatening cardiopulmonary diseases, including PAH, PH-ILD, IPF, and progressive pulmonary fibrosis. The commercial model depends heavily on specialist physicians who diagnose complex conditions, select pulmonary vasodilator therapies, and manage dosing over time.

The Q3 2026 transcript linked Tyvaso demand to referrals, new starts, increased dosing, patient demand, and physician engagement. The higher-dose cartridge program matters because management connected dose escalation with both revenue and patient retention.

Payer economics remain important. The 2025 10-K reported $238.9M of accrued rebates and chargebacks. Those deductions reflect government healthcare programs and other pricing arrangements, making gross-to-net management a recurring factor in reported revenue and margins.

Competitive Landscape

Merck (MRK) is the most important recent PAH entrant through Winrevair, an activin-signaling inhibitor approved by the FDA on March 26, 2024. Winrevair attacks PAH through a different mechanism than UTHR's prostacyclin products, which makes it a strategic competitor rather than a direct formulation substitute.

Johnson & Johnson (JNJ) competes through Opsumit and Uptravi. Uptravi is particularly relevant to Orenitram because both address the oral prostacyclin pathway. Liquidia (LQDA) competes directly in inhaled treprostinil through YUTREPIA, although the Q3 2026 settlement changed the competitive position in PH-ILD.

Generic competition is a larger issue for mature products. UTHR's 10-K identifies generic companies, YUTREPIA, and potential new therapies for PAH, PH-ILD, IPF, and progressive pulmonary fibrosis as competitive risks. The company retains a strong position, but the moat depends on differentiated delivery, clinical evidence, patents, and physician adoption rather than on market exclusivity alone.

Macro & Geopolitical Landscape

For UTHR, the most relevant macro forces are drug pricing, reimbursement, regulatory timing, and generic entry. Deloitte's 2026 life sciences outlook reported that 37% of respondents expected greater competitive pressure from generics and biosimilars, while 26% cited patent cliffs. Those industry figures reinforce risks already identified in UTHR's 10-K.

Regulatory timing is especially important because two major catalysts have fixed dates. The FDA's IPF decision for nebulized Tyvaso is scheduled for April 26, 2027, and the ralinepag PDUFA date is June 24, 2027. The soft-mist inhaler filing moved into 2027 after additional data requirements, showing how regulatory work can shift the timing of the growth narrative.

Supply-chain exposure is visible in the ralinepag API issue. UTHR's corrective-action work with the supplier and parallel contingency plans reduce the risk of a single point of failure, but the Official Action Indicated status gives the program a policy and manufacturing risk that is separate from clinical demand.

Balance Sheet Health

▌Premium Members Only

United Therapeutics held $1.56B in cash against just $7.3M of debt at year-end 2025, giving it an A+ balance sheet profile and ample flexibility for R&D and commercialization.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Q3 2026 revenue hit a record $832.5M, but diluted EPS slipped to $5.71 from $7.16 a year earlier as net income fell to $258.6M.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management is guiding the story toward 14 development programs, with FDA decisions for nebulized Tyvaso in IPF on April 26, 2027 and ralinepag in PAH on June 24, 2027.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At about $565, UTHR trades at 21.2x trailing earnings and 17.9x forward earnings, a fair but not cheap multiple for a company with a 2.2 PEG ratio and negative 20.3% earnings growth.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report’s valuation framework places the Buy threshold at $525 and the fair value at $675, leaving the stock above the buy zone but below the level that would justify a more cautious stance.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

United Therapeutics has the financial profile of a mature specialty pharmaceutical company and the pipeline profile of a growth biotech. The combination is unusual: $3.18B of 2025 revenue, $1.33B of net income, $1.04B of free cash flow, and almost no reported debt provide a durable base for continued investment.

The next phase depends on execution. Tyvaso must continue converting referrals into prescriptions, nebulized Tyvaso must secure the IPF label, ralinepag must clear the FDA process despite the API supplier issue, and the company must manage competition from Winrevair, Uptravi, YUTREPIA, and generics.

The evidence supports a Buy recommendation rather than an aggressive Strong Buy. UTHR has a strong balance sheet, high margins, a differentiated commercial franchise, and a clear 2027 catalyst calendar, but its 59.0% Tyvaso revenue concentration and recent EPS volatility justify valuation discipline. The $675 fair value estimate captures that balance between durable business quality and meaningful execution risk.

Why is United Therapeutics considered high quality?
United Therapeutics has $1.56B of cash, only $7.3M of debt, and an A+ balance sheet, which gives it unusual financial flexibility for a specialty biopharma. It also has a differentiated commercial franchise led by Tyvaso and a broad set of late-stage programs that extend beyond its current $3.18B commercial base.
+What are the biggest risks for UTHR stock?
The biggest risk is concentration: Tyvaso made up 59.0% of 2025 revenue, so any slowdown in that franchise would hit the whole company. The report also notes that Q3 diluted EPS fell to $5.71 from $7.16 and that competitive therapies pressured sales of nebulized Tyvaso, Tyvaso DPI, and Remodulin.
+What could drive UTHR higher from here?
The main upside drivers are continued Tyvaso growth and successful regulatory outcomes for nebulized Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension. Tyvaso already posted $503.8M in Q3 revenue, and the report highlights April 26, 2027 and June 24, 2027 as the key FDA decision dates.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on UTHR

More to read

All articles
United Therapeutics Corporation (UTHR) gains on deep earnings analysis
UTHR

United Therapeutics Corporation (UTHR) gains on deep earnings analysis

United Therapeutics Corporation (UTHR) posted a mixed quarter, missing EPS but beating revenue as shares gained on the session. This deep-dive looks beyond the headline, examining record Tyvaso sales, the Liquidia settlement, margin pressure, pipeline breadth, and why investors focused on growth over the earnings miss.

Nov 4·7 min
United Therapeutics Corporation (UTHR) gains after earnings misses
UTHR

United Therapeutics Corporation (UTHR) gains after earnings misses

United Therapeutics Corporation (UTHR) gains 0.3% even as earnings miss expectations, with investors weighing the latest results against the company’s outlook and pipeline progress.

Nov 4·1 min
United Therapeutics Corporation (UTHR) rises on patent win
UTHR

United Therapeutics Corporation (UTHR) rises on patent win

United Therapeutics Corporation (UTHR) rises after a Delaware court found Liquidia infringed two patent claims tied to inhaled treprostinil for PH-ILD. The ruling strengthens Tyvaso’s competitive position, while strong recent earnings and analyst support add to the bullish tone.

Oct 1·6 min